Content Type: Commentary & Opinion

User Fees and Beyond—The FDA Safety and Innovation Act of 2012

March 16, 2026

FDA Approval of Eteplirsen for Muscular Dystrophy (Reply)

March 16, 2026

Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities

March 16, 2026

Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs (Reply)

March 16, 2026

The Evolving Role of Biomarker Patents in Personalized Medicine

March 16, 2026

The Price of Crossing the Border for Medications

March 16, 2026

Simplify Drug Labelling to Show Benefits Clearly

March 16, 2026

Few New Drugs Deserve Expedited Regulatory Treatment

March 16, 2026

The Perils of Increasing Medicaid Rebates for Drugs with Accelerated Approval

March 16, 2026

Government Pharmaceutical Development to Address High Prices: Challenges Ahead

March 16, 2026

Why High Drug Pricing Is A Problem for Research Ethics

March 16, 2026

Ethical Challenges in Biomarker-Driven Drug Development

March 16, 2026